Implantable cardioverter-defibrillator

St. Elizabeth Healthcare First in Kentucky to Implant New Device To Treat Abnormal Heart Rhythm

Retrieved on: 
Friday, February 16, 2024
Cardiac electrophysiology, EV, FDA, Cardiology, Food, Heart rate, Arrhythmia, Tachycardia, Vein, Heart failure, ATP, Medtronic, Heart, Arrest, Implantable cardioverter-defibrillator

J. Christian Hays, MD , Director of Cardiac Electrophysiology at St. Elizabeth Healthcare, performed the procedure on January 12, 2024.

Key Points: 
  • J. Christian Hays, MD , Director of Cardiac Electrophysiology at St. Elizabeth Healthcare, performed the procedure on January 12, 2024.
  • Implantable cardioverter-defibrillators (ICDs) are devices doctors implant in the upper chest to treat arrhythmias.
  • If it detects an irregular heart rhythm or one that's too fast, the device sends an electrical signal through the lead to the heart.
  • Learn more about cardiology services offered at St. Elizabeth Healthcare or contact us at 859-331-3353.

Global Pacemakers Pipeline Insight and Competitive Landscape 2022: Featuring Key Players Medtronic, Boston Scientific Corporation, Biotronik Se & Co, LivaNova & Abbott Laboratories - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 27, 2022
Biotechnology, Health, Medical Devices, Acquisition, Blood, Physician, Competitive landscape, Food, CRT, Metal electrode leadless face, Degenerative disease, UCLA, Implantable cardioverter-defibrillator, News, Heart failure, Food and Drug Administration, Ageing, Technology, FDA, High, Heart, Medtronic, Growth, Cardiac arrest, Population, THI, The Texas Heart Institute, Nature, Prevalence, Medical device, Oil, Artificial cardiac pacemaker

This "Pacemakers-Pipeline Insight and 2022," report provides comprehensive insights about 20+ companies and 25+ pipeline devices in Pacemakers pipeline landscape.

Key Points: 
  • This "Pacemakers-Pipeline Insight and 2022," report provides comprehensive insights about 20+ companies and 25+ pipeline devices in Pacemakers pipeline landscape.
  • The Pacemakers market is expected to undergo significant growth in the approaching years owning to an increasing prevalence of cardiovascular disorders around the world.
  • This report provides a detailed study of the emerging pacemakers along with competitive landscape to help better understand the emerging pacemaker devices.
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

The Worldwide Electrophysiology Industry is Expected to Reach $11.9 Billion by 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 21, 2022
Health, Medical Devices, Cardiology, CAGR, Population, Stryker, Union, WHO, Atrial flutter, Budget, World, CE marking, Risk, Smartphone, Dyslipidemia, Hospital, USD, Disease, Hypertension, Stroke, EP, World Health Organization, Incidence, AED, Prevalence, Heart, Canadian International Council, CVD, Death, Person, American Heart Association, Heart failure, Suds, WPW, Pandemic, Ban on caffeinated alcoholic drinks, Industry, FDA, Abbott Laboratories, Atrial fibrillation, Electrophysiology, Adoption, AVNRT, Catheter, Laboratory, Diagnosis, Medical tourism, Diabetes, US Foods, Mortality, Obesity, Cardiovascular disease, Arrhythmia, ICE, ICM, Tobacco smoking, Food, Product life-cycle theory, ICDS, Awareness, Liquor, Medical device, Pharmaceutical industry, Recycling, Implantable cardioverter-defibrillator

The Global Electrophysiology Market size is expected to reach $11.9 billion by 2028, rising at a market growth of 8.8% CAGR during the forecast period.

Key Points: 
  • The Global Electrophysiology Market size is expected to reach $11.9 billion by 2028, rising at a market growth of 8.8% CAGR during the forecast period.
  • Electrophysiology (EP) devices are a type of medical equipment that is used to diagnose and treat cardiovascular problems.
  • In the event of an emergency, these devices send & receive electrical signals to & from the heart to regulate the heartbeat.
  • According to the WHO organization, CVD expenses is expected to reach USD 1,044 billion by 2030, up from USD 863 billion in 2010.

The Worldwide Implantable Defibrillators Industry is Expected to Reach $5.6 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 4, 2022
Medical Devices, Health, Atrial fibrillation, Arrhythmia, Insurance, MRI, Infarction, Ventricular tachycardia, Ventricular fibrillation, Implantable cardioverter-defibrillator, Abdomen, ICD, Patient, Electrode, Incidence, ICDS, History, Skin, Arrest, Magnetic resonance imaging, Palpitations, CAGR, SCA, Boston Scientific, Technology, Heart, Growth, Ventricular septal defect, Heart rate, Medical device

The "Implantable Defibrillators Market: Global Opportunity Analysis and Industry Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Implantable Defibrillators Market: Global Opportunity Analysis and Industry Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global implantable defibrillators market was valued at $3,300.00 million in 2020, and is projected to reach $5,612.62 million by 2030, registering a CAGR of 5.3% from 2021 to 2030.
  • Implantable defibrillators are battery-powered small devices placed underneath the chest or abdomen to keep track of a patient's heart rate.
  • It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market

Global Cardiac Bio Implant Devices Market Report 2022: Forecasts, Industry Trends, Growth, Insight, Impact of COVID-19, Company Analysis, 2021-2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 3, 2022
Medical Devices, Health, COVID-19, Globe, Cardiac resynchronization therapy, Projection, Degenerative disease, Mortality, CRT, Budget, Stroke, Insight, Moyamoya disease, Heart failure, Management of heart failure, Oxygen, Cardiovascular disease, CRTS, Prevalence, Implantable cardioverter-defibrillator, Sudden death, Diabetes, Blood, Obesity, ICDS, Conditional sentence, Smoking, CSR, CAGR, Lists of schools in England, Alcoholism, Nutrient, Awareness, Hypertension, Risk, Medical device, Pharmaceutical industry, Death, Arrhythmia, Artificial cardiac pacemaker, Growth

The "Global Cardiac Bio Implant Devices Market, Size, Forecast 2022-2027, Industry Trends, Growth, Insight, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cardiac Bio Implant Devices Market, Size, Forecast 2022-2027, Industry Trends, Growth, Insight, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Hence, Cardiac Bio Implant Devices are electronic or mechanical implantable devices developed to aid in the treatment of cardiac disorders.
  • The increasing prevalence and awareness of cardiovascular disorders drive the Global Cardiac Bio Implant Devices Market.
  • However, the global Cardiac Bio Implant Devices market recovered as different government authorities began to break the enforced lockdowns in 2020.

Jewish National Fund-USA Philanthropic Giant, Inventor of the Implantable Defibrillator Remembered

Retrieved on: 
Wednesday, April 27, 2022
Water, Travel, Implantable cardioverter-defibrillator, Civilization, Tree of life, Russell, National, Cardiac resynchronization therapy, Toby, World, Mower, CRT, Heart, ICD, Negev, Robin, The Next Decade (book), Heritage, Refugee, Jews, Council, Ecology, Zionism, Renewable energy

"Dr. Mower loved Israel with a passion beyond words," said Jewish National Fund-USA President, Dr. Sol Lizerbram.

Key Points: 
  • "Dr. Mower loved Israel with a passion beyond words," said Jewish National Fund-USA President, Dr. Sol Lizerbram.
  • "He even made it his mission last month to travel back to Israel with Jewish National Fund-USA to see the land and its people that he cherished so dearly.
  • Because of Dr. Mower and his dear wife, Dr. Toby Mower, their philanthropic footprint is felt and seen throughout our Jewish homeland."
  • The Mowers were also recipients of Jewish National Fund-USA's highest honors, including the Tree of Life and Heritage awards.

Global Defibrillator Market Forecast to 2028 - COVID-19 Impact and Analysis - ResearchAndMarkets.com

Retrieved on: 
Monday, March 21, 2022
Health, Medical Devices, Cardiology, Risk, CAGR, Heart, External, Emergency, ICD, VF, Cardiac arrest, Degenerative disease, Growth, Patient, Arrhythmia, CVD, Defibrillation, Puhua International Hospital and Clinics, Incidence, Prevalence, Industry, Time, COVID-19, VT, Geography, Cardiopulmonary resuscitation, Awareness, Ventricular fibrillation, Hospital, Public Access, Medical device, Marketing, Implantable cardioverter-defibrillator

The "Defibrillator Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type, End User, and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Defibrillator Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type, End User, and Geography" report has been added to ResearchAndMarkets.com's offering.
  • The defibrillator market is projected to reach US$ 14,876.95 million by 2028 from US$ 10,478.31 million in 2021.
  • The Implantable cardioverter defibrillator segment is expected to hold the largest share of 68.80% of the defibrillator market in 2021.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

Global Implantable Cardioverter Defibrillators (Cardiovascular) Market Report 2022 Featuring Medtronic, Abbott Laboratories, Boston Scientific, Biotronik, & MicroPort Scientific - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 16, 2022
Health, Cardiology, Arrhythmia, SWOT, Market access, Region, Country, Forecast model, Ventricular fibrillation, Patient, Cardiomyopathy, Coronary artery disease, Review, Ventricular tachycardia, Implantable cardioverter-defibrillator, COVID-19, Defibrillation, SCA, Cardiac arrest, Pulse, Blood, Epidemiology, Heart, Industry, Medical device, Retail, Healthcare

The "Implantable Cardioverter Defibrillators (Cardiovascular) - Global Market Analysis and Forecast Model" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Implantable Cardioverter Defibrillators (Cardiovascular) - Global Market Analysis and Forecast Model" report has been added to ResearchAndMarkets.com's offering.
  • Implantable Cardioverter Defibrillators (Cardiovascular) - Global Market Analysis and Forecast Model (COVID-19 Market Impact) is built to visualize quantitative market trends within Cardiovascular Devices therapeutic area.
  • The model discusses in detail the impact of COVID-19 on Implantable Cardioverter Defibrillators market for the year 2020 and beyond.
  • Global, Regional and Country level market specific insights:
    Qualitative market specific information is available with global trends further broken down into regional trends.

Impulse Dynamics Announces First Patient Enrolled in AIM HIGHer — Implantable Device Trial to Treat Heart Failure in Higher EF Population

Retrieved on: 
Monday, March 14, 2022
NCT, CRT, Heart, Section, Implantable cardioverter-defibrillator, Cleveland Clinic, Twitter, Trial of the century, University, NYHA, Patient, Mortality, Â, MPH, AIM, Hope, FDA, Higher, Associate, IDE, Mathematical optimization, Quality of life, CCM, Heart failure, Disease, MBA, GLOBE, Doctor of Philosophy, SVP-24, SVP, Assessment, Population, Narek, HF, Cleveland, CEO, EF, LinkedIn, Pharmaceutical industry, Medical device, Facebook, Electrophysiology, MD, Medicine

Simos Kedikoglou, MD, CEO of Impulse Dynamics, said, AIM HIGHer is another example of our continuous investment in CCM therapy for the benefit of HF patients.

Key Points: 
  • Simos Kedikoglou, MD, CEO of Impulse Dynamics, said, AIM HIGHer is another example of our continuous investment in CCM therapy for the benefit of HF patients.
  • AIM HIGHer is a remarkable study in several respects, said Ishu Rao, MD, Medical Director for Impulse Dynamics.
  • CCM therapy is a promising approach to treat these patients, and the AIM HIGHer trial will provide much-needed evidence in this area.
  • This trial will evaluateCCM therapy in heart failure patients with an EF over 40% a group that currently has few treatment options.

Global Implantable Cardioverter Defibrillators (ICD) Landscape: Pipeline Insight and Competitors 2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 22, 2022
Pharmaceutical, Consumer, Medical Devices, Hospitals, Science, Surgery, Cardiology, Biotechnology, Seniors, Medical Supplies, Other Science, Health, Infarction, Degenerative disease, Awareness, Competitive landscape, Implantable cardioverter-defibrillator, Technology, ICD, Population, Prevalence, Incidence, Life, Medical device

The "Implantable Cardioverter Defibrillators (ICD)-Pipeline Insight and Competitive Landscape, 2022" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Implantable Cardioverter Defibrillators (ICD)-Pipeline Insight and Competitive Landscape, 2022" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Implantable Cardioverter Defibrillators (ICD)-Pipeline Insight and Competitive Landscape, 2022" report provides comprehensive insights about 20+ companies and 20+ pipeline devices in the Implantable Cardioverter Defibrillators (ICD) pipeline landscape.
  • This report provides a detailed study of the emerging Implantable Cardioverter Defibrillators (ICD) along with competitive landscape to help better understand the emerging Implantable Cardioverter Defibrillators (ICD).
  • What are important and diverse types of Implantable Cardioverter Defibrillators (ICD) under development?